THOMAS KOSTEN to Tobacco Use Disorder
This is a "connection" page, showing publications THOMAS KOSTEN has written about Tobacco Use Disorder.
Connection Strength
1.733
-
The potential of pharmacogenomics to treat drug addiction. Pharmacogenomics. 2009 Dec; 10(12):1883-6.
Score: 0.303
-
Nicotine dependence, symptoms and oxidative stress in male patients with schizophrenia. Neuropsychopharmacology. 2007 Sep; 32(9):2020-4.
Score: 0.248
-
Effects of topiramate in combination with intravenous nicotine in overnight abstinent smokers. Psychopharmacology (Berl). 2006 Mar; 184(3-4):645-51.
Score: 0.232
-
A placebo controlled trial of bupropion for smoking cessation in schizophrenia. Biol Psychiatry. 2002 Jul 01; 52(1):53-61.
Score: 0.181
-
The potential of dopamine agonists in drug addiction. Expert Opin Investig Drugs. 2002 Apr; 11(4):491-9.
Score: 0.178
-
Altered habenula resting state functional connectivity in deprived veteran tobacco smokers: A pilot study. Bull Menninger Clin. 2020; 84(1):21-34.
Score: 0.153
-
Withdrawal Symptoms and Nicotine Dependence Severity Predict Virtual Reality Craving in Cigarette-Deprived Smokers. Nicotine Tob Res. 2015 Jul; 17(7):796-802.
Score: 0.107
-
BDNF Val66Met variant and smoking in a Chinese population. PLoS One. 2012; 7(12):e53295.
Score: 0.094
-
Brain-derived neurotrophic factor polymorphisms and smoking in schizophrenia. Schizophr Res. 2007 Dec; 97(1-3):299-301.
Score: 0.065
-
Association of functional catechol O-methyl transferase (COMT) Val108Met polymorphism with smoking severity and age of smoking initiation in Chinese male smokers. Psychopharmacology (Berl). 2007 Mar; 190(4):449-56.
Score: 0.062
-
Therapeutic vaccines for substance dependence. Expert Rev Vaccines. 2004 Feb; 3(1):11-8.
Score: 0.051
-
Therapeutic vaccines for substance dependence. Expert Rev Vaccines. 2002 Oct; 1(3):363-71.
Score: 0.046
-
Treatment of patients with substance use disorders, second edition. American Psychiatric Association. Am J Psychiatry. 2007 Apr; 164(4 Suppl):5-123.
Score: 0.016